Procept Biorobotics Corp

Common Name
Procept Biorobotics
Country
United States
Sector
Healthcare
Industry
Medical Devices
Employees
756
Ticker
PRCT
Exchange
NASDAQ/NMS
Description
Procept BioRobotics Corporation focuses on developing and commercializing surgical robotics technology. The company's flagship product, AquaBeam Robotic System, is designed to treat lower urinary trac...

Financial Statements of Procept Biorobotics

Below are the financial statements of Procept Biorobotics, including the income statement and balance sheet for the company's latest fiscal year. All figures are accurate, verifiable, and fully traceable to the original annual filing where disclosed.

All figures in millions of USD202420232022
Revenue
224.5a
136.19a
75.01a
Cost of sales
-87.4a
-65.14a
-37.93a
Gross profit
137.1a
71.05a
37.09a
Operating expenses
Research and development
-62.3a
-48.45a
-28.98a
Selling, general and administrative
-171.42a
-131.77a
-88.83a
Total operating expenses
-233.71a
-180.22a
-117.81a
Loss from operations
-96.61a
-109.17a
-80.72a
Interest expense
-4.18a
-4a
-5.18a
Interest and other income, net
9.39a
7.27a
2.01a
Loss on loan extinguishment
0a
0a
-3.26a
Net loss
-91.41a
-105.9a
-87.15a

Verified Sources Behind Procept Biorobotics’s Financial Fundamentals Data

Every figure on this dashboard has a transparent audit trail. With Tracenable, each data point is traceable back to its original source, viewable directly inside our platform. Explore Procept Biorobotics’s data sources below and access millions more through our Disclosure Search.

a. Procept Biorobotics's 10-K 2024
Trace every data point back to Procept Biorobotics’s disclosures

Sign up for Tracenable and access millions of corporate disclosures, including annual reports and sustainability filings from global companies, completely free of charge.

Real-Time & Standardized Financials

Access Standardized Financial Statements within Minutes of Disclosure

At Tracenable, we're exploring the launch of real-time standardized financial datafeeds and APIs covering global equities. Unlike limited and inconsistent XBRL parsing, our approach aims to deliver clean, comparable, and fully traceable data seconds after publication.

Could this solution support your investment or analytical workflows?